Virtus Biotech Clinical Trials ETF
BBC
21 hedge funds and large institutions have $15.2M invested in Virtus Biotech Clinical Trials ETF in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
11% more funds holding
Funds holding: 19 → 21 (+2)
4.45% more ownership
Funds ownership: 36.99% → 41.44% (+4.4%)
4% less capital invested
Capital invested by funds: $15.7M → $15.2M (-$550K)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTUS
Flow Traders U.S.
New York
|
+$1.44M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$249K |
| 3 |
LPL Financial
San Diego,
California
|
+$205K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$54.9K |
| 5 |
ODG
O'Dell Group
Cincinnati,
Ohio
|
+$5.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$382K |
| 2 |
Morgan Stanley
New York
|
-$325K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$249K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$204K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$9.81K |
BBC Hedge Fund Activity: Q3 2021 in Review
21 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q3 2021, worth a combined $15.2M — down 3.5% from $15.7M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BBC positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Flow Traders U.S., adding an estimated $1.44M. The largest seller was Cetera Investment Advisers, cutting an estimated $382K.
- 21 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q3 2021, up from 19 in Q2 2021.
- Funds reported $15.2M of Virtus Biotech Clinical Trials ETF stock for Q3 2021, down 3.5% quarter-over-quarter.
- 3 funds opened new Virtus Biotech Clinical Trials ETF positions in Q3 2021 and 1 closed out, a net change of +2 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q3 2021 was Flow Traders U.S., an estimated $1.44M added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q3 2021 was Cetera Investment Advisers, an estimated $382K sold.
Based on aggregated 13F filings for Q3 2021.